Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q21011234> ?p ?o }
Showing triples 1 to 70 of
70
with 100 triples per page.
- Q21011234 subject Q8256055.
- Q21011234 subject Q8919936.
- Q21011234 abstract "Edoxaban (DU-176b, trade names Savaysa, Lixiana) is an oral anticoagulant drug which acts as a direct factor Xa inhibitor. It was developed by Daiichi Sankyo and approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism.".
- Q21011234 atcPrefix "none".
- Q21011234 bioavailability "62.0".
- Q21011234 casNumber "912273-65-5".
- Q21011234 chEBI "85973".
- Q21011234 fdaUniiCode "NDU3J18APO".
- Q21011234 iupacName "N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide".
- Q21011234 pubchem "25022378".
- Q21011234 thumbnail Edoxaban.svg?width=300.
- Q21011234 wikiPageExternalLink edoxaban.html.
- Q21011234 wikiPageWikiLink Q101026.
- Q21011234 wikiPageWikiLink Q107231.
- Q21011234 wikiPageWikiLink Q12202.
- Q21011234 wikiPageWikiLink Q131130.
- Q21011234 wikiPageWikiLink Q14821011.
- Q21011234 wikiPageWikiLink Q14861061.
- Q21011234 wikiPageWikiLink Q14865111.
- Q21011234 wikiPageWikiLink Q1542839.
- Q21011234 wikiPageWikiLink Q1762339.
- Q21011234 wikiPageWikiLink Q179217.
- Q21011234 wikiPageWikiLink Q188151.
- Q21011234 wikiPageWikiLink Q190016.
- Q21011234 wikiPageWikiLink Q204711.
- Q21011234 wikiPageWikiLink Q215118.
- Q21011234 wikiPageWikiLink Q220570.
- Q21011234 wikiPageWikiLink Q267896.
- Q21011234 wikiPageWikiLink Q27205.
- Q21011234 wikiPageWikiLink Q2750727.
- Q21011234 wikiPageWikiLink Q275466.
- Q21011234 wikiPageWikiLink Q2852541.
- Q21011234 wikiPageWikiLink Q304088.
- Q21011234 wikiPageWikiLink Q381899.
- Q21011234 wikiPageWikiLink Q407431.
- Q21011234 wikiPageWikiLink Q414462.
- Q21011234 wikiPageWikiLink Q420262.
- Q21011234 wikiPageWikiLink Q421218.
- Q21011234 wikiPageWikiLink Q423640.
- Q21011234 wikiPageWikiLink Q468787.
- Q21011234 wikiPageWikiLink Q487937.
- Q21011234 wikiPageWikiLink Q4898219.
- Q21011234 wikiPageWikiLink Q496997.
- Q21011234 wikiPageWikiLink Q5222570.
- Q21011234 wikiPageWikiLink Q652297.
- Q21011234 wikiPageWikiLink Q65979.
- Q21011234 wikiPageWikiLink Q669441.
- Q21011234 wikiPageWikiLink Q815819.
- Q21011234 wikiPageWikiLink Q8256055.
- Q21011234 wikiPageWikiLink Q83042.
- Q21011234 wikiPageWikiLink Q841215.
- Q21011234 wikiPageWikiLink Q8919936.
- Q21011234 wikiPageWikiLink Q906280.
- Q21011234 wikiPageWikiLink Q9368.
- Q21011234 wikiPageWikiLink Q9377.
- Q21011234 atcPrefix "none".
- Q21011234 bioavailability "-7200.0".
- Q21011234 casNumber "912273".
- Q21011234 chebi "85973".
- Q21011234 iupacName "N'--N-[-4--2-[amino]cyclohexyl]oxamide".
- Q21011234 pubchem "25022378".
- Q21011234 unii "NDU3J18APO".
- Q21011234 type ChemicalSubstance.
- Q21011234 type Drug.
- Q21011234 type ChemicalObject.
- Q21011234 type Thing.
- Q21011234 type Q8386.
- Q21011234 comment "Edoxaban (DU-176b, trade names Savaysa, Lixiana) is an oral anticoagulant drug which acts as a direct factor Xa inhibitor. It was developed by Daiichi Sankyo and approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism.".
- Q21011234 label "Edoxaban".
- Q21011234 depiction Edoxaban.svg.